INDIANAPOLIS, May 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor), olomorasib (an investigational KRAS G12C inhibitor) and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.
Eli Lilly has in the past few months unveiled two back-to-back trial flops for Verzenio in prostate cancer. Now, we know exactly how one sputtered.
Eli Lilly has announced that its net income on a reported basis rose to $2.24bn for the first quarter (Q1) of 2024, a 67% increase from $1.34bn in the same period of the previous year.
Lilly’s growth drivers, Verzenio and Jardiance, suffer setbacks
Verzenio failed to significantly prolong the time before tumor progression or death when added to Johnson & Johnson’s Zytiga and the corticosteroid prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC), Lilly said Tuesday alongside its fourth-quarter financial results.
Eli Lilly culled a Phase III trial testing its cancer drug Verzenio in patients with castration-resistant prostate cancer after it failed to improve progression-free survival in men with the disease, the Indianapolis-based drugmaker said Monday.
INDIANAPOLIS, Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 3 clinical trial, which will be presented in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (SABCS). MONARCH 3 evaluated Verzenio® (abemaciclib) in combination with an aromatase inhibitor (AI) compared to an AI alone as initial endocrine-based therapy for post-menopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. At eight years of follow-up, MONARCH 3 showed women taking Verzenio and an AI had a median overall survival (OS) of more than 5.5 years – an increase of 13.1 months compared to the control arm in the intent-to-treat (ITT) population (66.8 vs 53.7 months), although statistical significance for the OS outcome was not reached (HR, 0.804; 95% CI, 0.637-1.015; p=0.0664).
Designation is for 2nd or 3rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor Data updates and further development plans to be...
INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced five-year outcomes from a pre-planned analysis of the Phase 3 monarchE study evaluating two years of adjuvant Verzenio® (abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. These data were shared in a late-breaking presentation at the 2023 European Society for Medical Oncology (ESMO) Congress.
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors